1. Pomerantz LLP investigates ADC Therapeutics for potential securities fraud. 2. ADC announced positive data from LOTIS-7 trial but noted adverse events. 3. Stock dropped 14.13% following the announcement on December 3, 2025.
FAQ
Why Bearish?
The investigation into potential securities fraud can lead to loss of investor confidence, similar to past cases like Valeant Pharmaceuticals, which saw stock plunge due to ongoing investigations.
How important is it?
The ongoing investigation and associated stock drop indicates serious concerns over ADC's operational integrity, directly influencing investor perceptions and potential pricing.
Why Short Term?
Immediate market reactions to legal investigations are generally swift, as investors often sell off quickly to mitigate risk.
Investor Alert: Pomerantz Law Firm Investigates ADC Therapeutics (ADCT) Claims
Pomerantz LLP has initiated an investigation focusing on potential claims for investors of ADC Therapeutics SA (NYSE: ADCT). This investigation aims to assess if the company and its officers or directors may have participated in securities fraud or other illegal business practices.
Details of the Investigation
Investors in ADCT who believe they may have been harmed are encouraged to reach out to Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980. The inquiry centers on specific communications from ADC Therapeutics that could indicate wrongdoing.
Recent Clinical Trial Data Release
On December 3, 2025, ADC Therapeutics released updated information from the LOTIS-7 Phase 1b open-label clinical trial, which assesses the safety and efficacy of ZYNLONTA® when combined with the bispecific antibody glofitamab (COLUMVI®). The findings pertained to patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
While the press statement highlighted positive outcomes, it also mentioned significant adverse events, with two patients experiencing treatment-related effects. Notably, cytokine release syndrome of all grades was reported in 36.7% of the patients across various dose levels.
Impact on ADC Therapeutics (ADCT) Stock Price
Following the release of this data, shares of ADCT dropped by $0.65, translating to a 14.13% decrease, closing at $3.95 per share on December 3, 2025. This dramatic decline raises concerns regarding the potential impact of the trial results on investor sentiment and the company's reputation.
About Pomerantz LLP
Pomerantz LLP is a distinguished law firm with a reputation for excellence in corporate, securities, and antitrust class litigation. With offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has been at the forefront of securities class actions for over 85 years. Established by the late Abraham L. Pomerantz, the firm continues to advocate for victims of securities fraud and corporate misconduct.
Throughout its history, Pomerantz has achieved significant recoveries for its class members, reinforcing its status as a leader in the field of class action litigation.
For more information, please visit www.pomlaw.com.
Contact Information
For inquiries related to this investigation, please contact:
- Danielle Peyton
- Pomerantz LLP
- Email: [email protected]
- Phone: 646-581-9980 ext. 7980